Chronic kidney disease is a major global health problem with an increasing prevalence. By 2040, it is estimated that CKD will have become the fifth leading cause of death. This increasing CKD burden is driven in part by aging population structure (CKD is ~8x more common in adults > 70 years old compared to persons < 40 years of age). Diabetes and hypertension are common risk factors for kidney damage and are therefore major contributors to the increased CKD prevalence.
There is a marked gender imbalance in CKD with a higher incidence (11.0 vs. 9.6 per 1,000 person-years) and higher prevalence (16.0% vs. 12.4%) in women. Nevertheless, women have a lower risk of CKD progression and men are more likely to develop ESRD.
Chronic kidney disease is a complex heterogeneous disease, with contributions from both genomic and environmental factors. CKD heritability has been estimated to be high (30-75%). CKD can be identified by well-established clinical biomarkers such as SCr levels, eGFR, albuminuria, or UACR. Unfortunately, these clinical biomarkers are limited in their utility to predict individual risk of CKD or likelihood for later progression to ESRD. Major efforts have been made to understand the heritability in CKD but the causal pathways remain incompletely understood. Four major approaches have been proposed to uncover the missing heritability; exploration of rare variants, increased samples sizes, study of molecular factors not involving variants in the DNA sequence and consideration of whether family studies overestimated heritability risk. In CKD, meta-analyses of GWAS have provided a useful and relatively inexpensive strategy to increase the statistical power by combining data summaries from different individual GWAS, helping to attenuate the issue of small sample size and identifying many genetic loci associated with CKD and/or kidney function traits. Rare variants in UMOD, SHROOM3, solute carriers, and E3 ubiquitin ligases have also been associated with CKD, eGFR or SCr. However, these genetic markers do not account for all the susceptibility to CKD, therefore other factors must be contributing to the missing heritability. Part of the missing heritability may correspond to genetic interactions (epistasis), rather than to missing variants. Telomere length is a biological factor that has been associated with CKD prevalence and/or CKD progression in a small number of studies. Structural variants, such as CNVs, insertions, deletions, inversions and translocations are, in general, poorly covered in commercial arrays and may explain part of the missing heritability. Mitochondrial proteins, encoded by nuclear genes, and specific mtDNA encoded genes have also been associated with CKD. The sex chromosomes, often excluded from GWAS studies, may help explain gender imbalances in CKD.
In this review, we outline some recent findings on molecular biomarkers for CKD (telomeres, CNVs, mtDNA variants, X and Y chromosomes) that typically have received less attention than single nucleotide polymorphisms (SNPs) present on, or imputed from, GWAS arrays. These less commonly studied biomarkers may be part of the "missing heritability" for CKD.
Telomeres are specialized nucleoprotein complexes that help protect the ends of linear chromosomes. There are inter-individual and intra-individual differences in the length of telomeres. Shorter telomere length has been associated with multi-system diseases, early life stressors, increasing chronological age and all-cause mortality (Figure 1). The majority of studies have analyzed relative telomere length in peripheral blood leukocytes, but telomere length differs between tissues within a single individual, with greater heterogeneity in telomere length evident in older people. Telomere length has a reported heritability of 28-82%, however, not all genetic factors or environmental influences on telomere length are known. Meta-analysis of telomere length may help confirm discovery associations across multiple collections, however, this is challenging with different wet-lab techniques (such as time at sample collection, storage and processing of biological material, absolute compared to relative telomere length evaluation, platform employed) and in silico analyses (such as normalization, controls, covariates, association, and correction tools) having significant effects on the reported measurements. There is also limited traditional epidemiological evidence exploring the mechanistic basis or causality of reported associations.
Nonetheless, there is evidence that telomere length is associated with disease states, particularly age-related diseases, beyond the most commonly studied cancers. Conflicting reports have been published for the association of telomere length with renal disease, however, most publications, albeit in relatively small sample sizes with modest significance values, report that shorter telomere length is associated with renal dysfunction. Shorter telomeres have been reported as associated with progression of CKD (defined as a doubling of baseline SCr and/or ESRD), in the MMKD (n = 59 patients had confirmed CKD progression) and CRISIS (n = 105 patients had confirmed CKD progression) studies, with the effect size strengthened by smoking and the presence of diabetes. Telomere shortening has been associated with IgAN in 177 patients, but not in 30 patients with DKD or 30 patients with FSGS compared to 83 controls. A study examining DNA from peripheral blood and urine in 15 patients with IgAN showed shorter telomere length correlated with declining renal function. Multiple studies have been performed for DKD, with the majority linking shorter telomere length to the development and progression of kidney disease in people with both type 1 (, 273 patients, 176 patients, 21 progressed) and type 2 diabetes (, 168 patients, 17 patients, 501 patients, 691 patients). Shorter telomere length is associated with diabetic complications and all-cause mortality. The Heart and Soul Study is a longitudinal cohort of individuals with stable coronary heart disease; shorter telomere length at baseline and more rapid telomere shortening over 5 years were associated with reduced kidney function, but these changes were not significant when accounting for age. It is noteworthy that the largest study published considered less than 1,000 individuals, which provides limited power to draw robust conclusions in this era of mega-consortia studying the genetics of CKD.
Premature telomere shortening is associated with duration of dialysis treatment in terms of months to years. A cross-sectional study of 175 hemodialysis patients reported shorter telomere length in men with CKD, despite women having an older average age in this cohort; association of shorter telomeres was also observed with increasing age and male sex. Shorter telomeres were associated with CKD in 203 Japanese hemodialysis patients compared to 203 age and sex-matched controls without CKD, with shorter telomeres also associated with new onset cardiovascular events. A less reactive immune system is associated with healthy aging in the general population and ESRD enhances premature immunological aging with shorter telomeres observed in 137 patients with ESRD compared to 144 individuals without kidney disease.
Histologically normal and abnormal human kidney tissue samples from 24 individuals highlighted age-related shorter telomere length with telomeres typically shorter in the cortex than in the medulla. Premature senescence is an important feature of renal fibrosis that accelerates when cells are exposed to stressful environments such as more ROS and higher glucose. Increasing age and sex related telomere shortening is observed in kidneys, with shorter telomeres observed in male rats. Multiple animal models of kidney disease show telomere shortening associated with renal dysfunction, however, a careful experimental design is required for accurate telomere measurement. Exploring renal ischemia/reperfusion injury in wild-type and telomerase deficient mice also suggests that shorter telomeres impair recovery from acute kidney injury. Severe renal failure induces telomere shortening with rapid telomere loss observed during kidney transplantation in a rat model of chronic rejection. Tucker and colleagues demonstrated that high-intensity interval training was beneficial protecting against telomere erosion in a rat model of CKD.
Large-scale studies using carefully collected biological samples with harmonized phenotypes and analysis protocols will help determine the true association of telomere length for CKD. Potential therapies exist to minimize premature telomere shortening, but further work is needed to define the mechanistic links between telomere length and kidney function.
Copy number variants are genetic structural variants which involve DNA regions being deleted or duplicated. This can occur throughout the genome affecting stretches of DNA ranging from kilo- to mega-base pairs in length and can result in abnormal gene amplification. CNVs can be both inherited and arise de novo, and are increasingly being recognized as a significant source of genetic variation relating to both population diversity and disease, including renal diseases, neuropsychiatric diseases, and cancer.
There is often uncertainty about the genetic basis of CKD in pediatric patients, but recent studies have indicated that chromosomal microarrays have the potential to partly address this. assessed 419 children enrolled in the CKD in children (CKiD) study alongside 21,575 children and adults who had undergone microarray genotyping for non-CKD studies. CNV disorders were identified in 31 children with CKD and 10 known pathogenic genomic disorders were detected including HNF1B deletion at 17q12. A further 12 pathogenic genomic imbalances were identified using this technique, distributed evenly among patients diagnosed with congenital and non-congenital forms of CKD. Overall, large gene-altering CNVs were more common in the CKiD population compared with the controls (38 vs. 23%), but the specific genetic alterations identified in several of the individuals would require personalized recommendations in future healthcare.
Copy number variants have been linked to CAKUT. In a study by, DNA from 178 Australian children who presented with any abnormality associated with CAKUT was screened using SNP arrays. In total, CNVs were identified in 18 children, of which 11 children presented with genomic disorders of unknown significance. Of these 11 participants, four were reported as having duplications of 1q23.1, 4p16.1, 7q33, and 8q13.2q13.3 regions, containing genes NEPH1, SLC2A9, AKR1B1, and EYA1, respectively. Each of these genes have previously been associated with renal abnormalities.
In an investigation undertaken by, seven children with CAKUT were assessed from three unrelated families using array comparative genomics hybridization. Of these participants, one reportedly had ureterovesical junction obstruction and a 1.4 Mb deletion at 17q12, containing two genes, HNF1B, which has been previously associated with CAKUT, and ACACA.
A recent study published by, suggested whole exome sequencing (WES) as a viable method to detect CNVs in individuals with CAKUT. These investigators performed WES in 112 individuals from 62 families, to identify SNVs and CNVs in 35 genes previously related to CAKUT. They identified a de novo triplication in one family at 22q11, and overall, 6.5% of the individuals assessed in this investigation were shown to have pathogenic CNVs.
Posterior urethral valves are one of the most common causes of CKD in children. assessed the phenotypic effects of and relationship between renal outcomes and CNVs in 45 boys with PUV. In total, 13 CNVs were identified in 12 boys, two of which, at positions 3p25.1p25.2 and 17p12, were pathogenic in nature. Additionally, those CNVs identified which were > 100 kb in size, were significantly associated with earlier onset of renal failure in children with PUV.
Nephronophthisis (NPH) is a Mendelian genetic disease, which often leads to ESRD by around 13 years of age. sought to investigate the prevalence of NPH in adult-onset ESRD, through assessment of the CNVs in the NPHP1 gene (>90 kb) because a homozygous full gene deletion is a prominent cause of NPH. These investigators assessed 5,606 adult renal transplant recipients, 26 of whom showed evidence of the homozygous NPHP1 deletion, compared to none of the 3,311 controls. Despite this, only 12% of the patients with the homozygous NPHP1 gene deletion were clinically diagnosed with NPH.
Copy number variants have also been investigated in association with IgAN, which is the most common cause of primary glomerulonephritis. The multi-allelic CNV in the defensin alpha 1 and alpha 3 gene locus (DEFA1A3) was assessed in two independent IgAN cohorts of Chinese Han individuals. This locus can present as tandem repeats of a 19kb DNA stretch, containing one copy of either DEFA1 or DEFA3, and several bi-allelic polymorphisms. The protein products of DEFA1A3, human neutrophil peptides 1-3, are abundant neutrophil granule proteins and function in the regulation of both the complement system and pro-inflammatory cytokine production. Each of these have been previously linked with IgAN.
Evaluation of the presence of CNVs yields potentially useful clinical information, especially for pediatric individuals with CKD.
Copy number variants in the human genome are likely to contribute to healthy development, but have additionally been linked to several human diseases. The molecular mechanisms that trigger the formation of CNVs are not fully understood, but recurrent CNVs with common breakpoints reportedly arise through unequal meiotic or non-allelic homologous recombination. Recent evidence has suggested that de novo and non-recurrent CNVs may develop following either replicative errors, chromosome shattering or chromothripsis.
Replication stress occurring during DNA replication has been linked to the collapse of the DNA replication fork and creation of a single-ended double strand break. It has been considered that this could result in a high frequency of de novo CNVs. Both the fork collapse and strand break could result in the activation of damage checkpoint and repair pathways to correctly reactivate replication, thus preventing the creation of structural variants. However, CNVs are understood to be created if this reactivation occurs in an incorrect location using a template switch, or when an incorrect repair occurs, which joins two distant DNA breaks and causes a large deletion. Any present mutations which inhibit the ability of the cell to accurately respond to a collapsed fork, are thought to ultimately increase the formation of CNVs.
In the last decade, GWAS have become essential for investigating the genetic contribution to CKD, with over 50 germline genetic loci identified as biomarkers of kidney disease risk or associated with SCr, cystatin-C and/or microalbuminuria. The UMOD gene, coding for uromodulin, the most abundant urinary protein, is the gene with most of the consistently replicated genetic associations. Several common UMOD variants (rs12917707, rs4293393, rs11864909, rs13329952) are associated with both CKD and eGFR. More recently, the higher frequency in ESRD of another common UMOD variant (rs13333226), has been confirmed in 638 Chinese patients with ESRD and 366 controls. Several common variants in the myosin heavy chain type II isoform A (MYH9) gene have been associated with non-diabetic ESRD in African Americans. Common variants in APOL1 are also associated with non-diabetic ESRD. Common variants in ELMO1 gene have been associated with DKD and its progression to ESRD in several populations, although in this case with less consistency. A more recent meta-analysis of GWAS, including data from 133,413 individuals and subsequently replicated in 42,166 individuals, identified 24 new loci associated with eGFR (BCAS1, AP5B1, A1CF, PTPRO, UNCX, NFKB1, TP53INP2, KCNQ1, CACNA1S, WNT7A, TSPAN9, IGFBP5, KBTBD2, RNF32, SYPL2, SDCCAG8, ETV5, DPEP1, LRP2, SIPA1L3, INHBC, ZNF204, SKIL, and NFATC1). The trans-ethnic meta-analysis showed that 12 loci had fully consistent effect direction on eGFR across European, Asian and African individuals (SDCCAG8, LRP2, IGFBP5, SKIL, UNCX, KBTBD2, A1CF, KCNQ1, AP5B1, PTPRO, TP53INP2, and BCAS1). Regarding other measures of kidney function, a variant rs1801239 in the CUBN gene was proposed as a predictor of UACR and microalbuminuria in a meta-analysis of 63,153 individuals of European ancestry, and another variant in the same gene, rs10795433, has been associated with UACR in 5,825 individuals of European ancestry with diabetes compared to 46,061 without diabetes. A recent discovery GWAS of UACR in 382,500 unrelated European participants of the UK Biobank, a population-based cohort, reported 33 common variants, 20 of them sharing a consistent direction of effect with the study by, including CUBN, HOTTIP, LOC101927609, NR3C2, ARL15, SHROOM3, MAPKBP1, ICA1L, SNX17, LRMDA, SBF2, SPATA5L1, FUT1/IZUMO1 genes and additional variants in chromosomes 1, 2, 7, 14, and 15: rs10157710, rs12032996, rs1276720, rs17158386, rs2023844, rs2472297, rs4410790, rs6535594, rs702634, rs7654754, rs8035855, rs10207567, rs1047891, rs4665972, rs13394343, rs67339103, rs17368443, rs4288924, rs1145074, and rs838142. This GWAS also identified 11 common novel associations in CUBN, PRKCI, EFNA3-EFNA1, MIR548AR-LOC646736, COL4A4, SPHKAP-PID1, INC01262-FRG1, RIB1-LINC00861, and BAHCC1 genes. UACR had previously been associated with another common variant in SHROOM3 (rs17319721) in a meta-analysis of 31,580 and 27,746 Caucasian patients, although it did not reach GWA significance (pdiscovery = 1.9 x 10-6).
Although GWAS have successfully identified SNPs associations for the different traits associated with CKD, most of them are common DNA variants of small effect size. The proportion of phenotypic variance of eGFR explained by the 24 novel loci and the 29 previously identified by Pattaro et al. was 3.22%, therefore of limited help in CKD prediction.
An alternative to the concept of SNPs as single biomarkers is the use of PGRS, which provide individual estimates of the risk of presenting a determinate trait calculated from the combination of specific risks associated to SNPs. However, PGRS may provide only a partial solution in complex diseases. A recent analysis of 32 highly relevant traits related to five disease areas in 13,436 subjects of the Lifelines Cohort reported only 10.7% of the common-SNP heritability of these traits was explained by the different weighted PGRS, compiled from genome-wide significantly associated index SNPs based on previous GWAS. The percentage of variance explained by the PGRS for SCr, composed of three SNPs of high imputation quality (R2 > 0.5) was 0.2% for both weighted and unweighted PGRS. Addition of one low-quality SNP increased the variance up to 0.21% (weighted PGRS). For the eGFR PGRS, composed of 33 SNPs (high-quality), the percentage of variance was 1.6% for unweighted PGRS and 1.8% for the weighted PGRS. Addition of 19 low-quality SNPs increased the variance up to 2.01% (weighted PGRS). There were no high-quality SNPs associated with UACR, so it was not possible to construct this PGRS. The inclusion of one low-quality SNP explained 0.12% of the variance with both weighted and unweighted PGRS. The PGRS for urate, composed of 20 SNPs (high-quality), explained from 2.0 to 4.2%, depending if either an unweighted or weighted PGRS was considered. Addition of eight low-quality SNPs increased the variance up to 4.52% (weighted PGRS).
Next generation sequencing has an increasing role for both research and diagnosis of kidney disease. Recently, a NGS panel for a spectrum of genetic nephropathies, covering 301 genes, was designed and validated in a CLIA-approved laboratory. The assay showed excellent performance characteristics and was able to provide a specific molecular pathogenesis-based diagnosis in 46% of biopsies studied. An NGS panel covering all coding and regulatory regions of UMOD identified 119 genetic variants in 23 ESRD patients (compared to 22 controls without renal disease). Ninety of those variants were SNPs, 60 of them with minor allele frequency greater than 5%. Linkage disequilibrium allowed 20 SNPs to capture 100% of the alleles with a mean R2 of 0.97, providing a set of independent SNPs suitable for association analysis in larger cohorts.
Whole-exome sequencing provided a diagnosis in 22 out of 92 adults with CKD of unknown cause, familial nephropathy or hypertension (22/92; 24%). The confirmation of the clinical diagnosis by WES allowed the appropriate genetic counseling and screening for the family members of some affected patients and helped in clarifying or entirely reclassified the disease in other cases. WES also identified PARN haploinsufficiency as a new genetic cause of CKD in this study. The PARN gene encodes a poly(A)-specific ribonuclease which mediates the post-transcriptional maturation of the telomerase RNA component (TERC) and causes telomere disorders. Exome sequencing has recently identified 11 loci (p < 1 x 10-4) in eight genes (PLEKHN1, NADK, RAD51AP2, RREB1, PEX6, GRM8, PRX, APOL1) associated with T2DM-ESRD in 2476 cases and 2057 non-nephropathy control individuals of African American origin. However, exome data from 7974 self-identified healthy adults has recently demonstrated an implausibly high rate of candidate pathogenic variants for kidney and genitourinary diseases (1.4%), much higher than the prevalence of genetic renal/genitourinary disorders, even after stringent filtering criteria (removal of indels and minor allele frequency cutoffs of < 0.01% and <0.1% for dominant and recessive disorders, respectively). This overestimation of potential pathogenic variants may increase the burden of uncertain diagnoses and medical referrals rather than alleviate it, therefore minimizing the utility of exome sequencing in clinical practice.
Mitochondria are organelles which generate ATP through OXPHOS and thus represent the primary energy source for normal function of the cell and body. The majority of mitochondrial proteins are encoded by nuclear genes. However, mitochondria also have their own circular genome 16,569 base pairs long that contains 37 genes which encode 13 proteins of the electron transport chain essential for OXPHOS along with two rRNAs and 22 tRNAs. Mitochondrial dysfunction in kidney tissue may severely impact renal health and has previously been implicated in CKD development.
If mitochondrial metabolism is adversely affected by genetic variants it can result in kidney disease, sometimes as part of a wider clinical disorder. Somatic mtDNA mutations may be associated with aging, resulting in decline of mitochondrial function in older individuals. Increased levels of mtDNA mutations have previously been associated with several disorders including various forms of kidney disease (Figure 2).
Mitochondrial dysfunction can occur via a number of pathways, for example persistent hyperglycemia (associated with diabetes) results in increased tubular oxygen consumption, and in turn leads to hypoxia of the kidney tissue. Mitochondrial dysfunction can be associated with increased electron leakage from the respiratory chain during OXPHOS, which results in ROS being generated which can cause kidney injury including direct damage to DNA. Genetic variation in mtDNA (Figure 2) or nuclear genes (Figure 3) which influence mitochondrial function may impair respiratory chain complex activities leading to an increase in production of ROS resulting in a negative feedback loop, increasing mitochondrial dysfunction, OXPHOS defects and ROS generation along with a reduction in ATP production which leads to increased oxidative stress which may lead to uncontrolled autophagy, mitophagy, and further ROS production. Mitochondrial dysfunction, ROS generation and the resulting dysregulation of autophagic mechanisms may also lead to an upregulation of the intrinsic pathway of apoptosis which in turn leads to inflammation and fibrosis in the renal tubules and glomeruli.
Despite the mitochondrial genome being widely ignored in relation to CKD, a number of studies have identified mitochondrial genomic loci associated with specific forms of renal disease (Table 1). SNPs within MT-HV2, MT-CO1, and MT-CO2c have been associated with IgAN; the A3243G point mutation in the leucineUUR tRNA gene (MT-TL1) was identified in patients with FSGS, other forms of renal disease and in a male with a history of MELAS syndrome including kidney cancer, who rapidly developed renal failure after removal of the cancerous kidney. In general, mtDNA biomarkers have not been considered as potential biomarkers in association studies, therefore most findings concerning the mitochondrial genome in relation to CKD come from case reports. The MT-TW tRNA (m.5538 G > A) mutation was identified as causing FSGS in a male. The (m.547 A > T) and tRNAPhe (m.616 T > C) mutations were found in patients suffering from inherited tubulointerstitial kidney disease, who did not display typical symptoms of mitochondrial disease. A novel mutation in mtDNA (09155 A > G) was described in a Caucasian female with a history of renal disease, and symptoms of Maternally inherited deafness and diabetes (MIDD). Mutations in nuclear genes associated with mitochondrial function have also been associated with renal disease. The P99L mutation in the BCS1L gene was found in a female infant suffering from Neonatal Toni-Debre-Fanconi Syndrome, including renal tubulopathy. R45C and R56X mutations in the BCS1L gene were described in two siblings suffering from congenital lactic acidosis, including renal tubulopathy, and nine different mutations in FBXL4 were identified in nine individuals suffering from mitochondrial encephalomyopathy including renal tubular acidosis.
Despite the limited published literature, the known significance of the mitochondrial genome with relation to renal function and the multiple case reports relating to individuals suffering from renal dysfunction associated with mutations in mitochondrial or mitochondrial-associated genes, suggest that there exists considerable potential for genetic mutations, resulting in mitochondrial dysfunction, to contribute toward CKD.
In CKD research, despite the efforts of extensive GWAS and other genomic analyses in this area, a "blind spot" still exists in the form of X- and Y-chromosome analysis. Fifty-three of the 3,643 publications found in the online GWAS catalog (hosted by the National Human Genome Research Institute-European Bioinformatics Institute) examined CKD and/or kidney-associated traits. Over 450 genome-wide associations (p < 5 x 10-8) with renal disease and/or related traits were found at 140 loci across the genome (Table 2).
As depicted in Table 2, the number of associations per chromosome is the lowest for chromosome Y (no associations) and the fourth lowest number of associations for chromosome X (four associations). This is not surprising for chromosome Y. Historically thought of as a "genetic wasteland", association analyses usually exclude the Y-chromosome. Indeed, in the 53 studies examining renal disease/traits, only one included the Y-chromosome in the association analysis. Given that the Y-chromosome is the smallest and contains the fewest number of genes per number of base pairs, the lack of significant associations in this study is not unexpected.
However, for a chromosome of its size and gene content, the small number of associations found between X-chromosome SNPs and renal disease/traits raises questions as to why there are so few reported. Indeed, the only chromosomes with fewer reported associations are chromosomes 14 and 21, both of which are smaller and contain fewer genes than chromosome X. The lack of reported associations with sex chromosome SNPs could be due to a true lack of association or under-representation of sex chromosomes in GWAS.
Of the 53 GWAS in renal disease/traits, 10 are unclear as to whether X- and Y-chromosome SNPs were included in association analysis. Over half (62%) of the studies did not report sex chromosome association results, with many actively excluding the X- and Y-chromosomes from the association or meta-analysis stages. Of the 10 studies (18%) that explicitly state that the X-chromosome analysis was included, only one study found associations between X-chromosome SNPs and renal traits (SCr and eGFR) that reached genome-wide significance. Two SNPS, rs12845465, and rs5987107, were both associated with SCr and eGFR (p < 5 x 10-8). In only one study does Y-chromosome analysis appear to be included, where no SNPs reached genome-wide significance.
Therefore, with less than 20% of studies reporting X-chromosome results and Y-chromosome exclusion almost ubiquitous, it is not surprising that very few sex chromosome SNPs have shown association in studies of renal disease/traits. A possible explanation for sex chromosome exclusion is that traditional imputation methods call for the use of autosomes only. Even now that methods of X-chromosome imputation have been introduced, greater expertise is required and the X-chromosome is imputed separately from the autosomes, and these issues may lead some researchers to simply exclude it. The lack of reported analysis of X-chromosome SNPs in renal disease then leads to its exclusion from meta-analysis, as X-chromosome results are not common between all included studies. Poor genotyping of X-chromosome SNPs may also account for a reduced number of significant associations. Evidence has suggested that removal of X-chromosome SNPs during quality control is significantly more likely, due to a higher rate of chromosomal anomalies or missing call rate than autosomal SNPs. However, despite the successful imputation of the X-chromosome, chromosome Y lags behind. Despite recent efforts, haplogroup-based Y-chromosome imputation is still not widely used, with authors opting to instead use only directly genotyped SNPs.
The lack of sex chromosome inclusion in CKD GWAS may be one reason that the relationship between sex and CKD incidence/progression is so unclear. By regularly excluding these chromosomes from renal GWAS, we may miss SNPs that infer either increased CKD risk or protection to one gender in particular.
Traditionally, a greater risk of CKD incidence and progression to ESRD was associated with males. While current evidence still supports an increased rate of progression in men to ESRD, the risk inferred by gender on incidence of CKD is unclear. A study which used several definitions of incidence found that when using eGFR-based definitions of CKD (<60 ml/min/1.732), incident CKD was significantly higher in women than men (p = 0.02), but when using a minimum increase in SCr to detect CKD, men had a significantly higher incidence (p = 0.001). Gender adjustment occurs in eGFR calculation, which may explain this difference. A study conducted to develop a CKD risk score also found that female sex was associated with prevalent CKD (p = 0.02), as did a Turkish population study (p < 0.001). Additionally, a comprehensive review revealed that 38 studies found CKD was more prevalent in women, while 13 found it was more prevalent in men. Therefore, while women seem to make up a larger proportion of the individuals affected by CKD, affected men seem to progress at a much faster rate, highlighting the difference in the way that CKD affects men and women.
Clinical evidence and recent literature support a link between the sex chromosomes and impaired renal function. Arising as a result of a mutation in COL4A5 on chromosome X, Alport syndrome is caused by impaired production or function of collagen in various basement membranes throughout the body, including in the glomerulus. The condition is characterized by hearing loss, ocular abnormalities and progression to ESRD, where up to 30% of women reach ESRD by age 60 and the majority of affected males will require transplant or dialysis by their late twenties.